Corcept Therapeutics Incorporated (NASDAQ:CORT) said on Thursday that it presented results from its Phase 2 DAZALS study of ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Corcept Therapeutics has tried to cast its recent phase 2 amyotrophic lateral sclerosis (ALS) failure in a more flattering ...

Corcept Therapeutics' dazucorilant failed the primary ALS trial goal but showed improved survival outcomes and a safe profile ...

It’s been nearly a year since Charlottesville lost one of its most respected pediatricians. At 65, he was diagnosed with a ...

The Everylife Foundation for Rare Diseases is offering a new scholarship for U.S. students from the ALS community facing ...

The Mississauga fundraiser is among 22 ALS Canada fundraising walks across Ontario, which aim to raise $2 million.

Despite its growing role in tracking MS activity, serum neurofilament light chain lacks diagnostic specificity, experts say.

Opponents, including some lawmakers, physician groups and the New York State Catholic Conference have cited numerous concerns ...

This review highlights how air pollution and occupational inhalation exposures may contribute to neurodegenerative disorders ...

Event being held this weekend was started by Phil Lalonde, a longtime Pointe-Claire resident and soccer coach who is now ...

The global Oligonucleotide Synthesis Market, valued at US$8.9 billion in 2024 stood at US$10.5 billion in 2025 and is projected to advance at a resilient CAGR of 18.6% from 2025 to 2030, culminating ...